clopidogrel + fluvoxamine

Clopidogrel + fluvoxamine is a combination of two pharmaceutical agents used together, typically in patients who require both antiplatelet therapy and treatment for depression or obsessive-compulsive disorder. Clopidogrel is an antiplatelet agent that acts as a prodrug, requiring metabolic activation primarily by the cytochrome P450 enzyme CYP2C19 to exert its effect by irreversibly inhibiting the P2Y12 subtype of adenosine diphosphate (ADP) receptor on platelets, thereby reducing platelet aggregation. Fluvoxamine is a selective serotonin reuptake inhibitor (SSRI) used mainly for depression and anxiety disorders; it inhibits serotonin reuptake in the central nervous system and also acts as a potent inhibitor of several cytochrome P450 enzymes, notably CYP2C19. When administered together, fluvoxamine can significantly inhibit the metabolic activation of clopidogrel by blocking CYP2C19. This interaction reduces clopidogrel’s conversion to its active metabolite, leading to decreased antiplatelet efficacy and potentially increasing cardiovascular risk in patients relying on clopidogrel for secondary prevention[1][3][4][5][8]. The combination should generally be avoided unless no alternatives exist due to this clinically significant drug-drug interaction.